H.C. Wainwright downgraded Iterum Therapeutics (ITRM) to Neutral from Buy without a price target Despite Orlynvah’s recent launch, the company filed a petition to begin winding up procedures in Ireland, the analyst tells investors in a research note. The firm steps to the sidelines pending possible future clinical, commercial, and business development updates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM: